Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc.   Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its precision antibiotic therapies based on naturally […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!